NCT06719661Completed
The Impact of Clinical Pharmacist Intervention and Dapagliflozin as Add-On Therapy in the Management of Type 2 Diabetes Mellitus.
Source: ClinicalTrials.gov · Last updated 5 Jun 2025
Brief summary (registry, in English)
Diabetes mellitus is a progressive endocrine disease characterized by insulin deficiency with or without insulin resistance. Management of type 2 diabetes requires a comprehensive team following and monitoring the disease carefully. Dapagliflozin is a sodium-glucose co-transporter-2 (SGLT2) inhibitor, has been shown to be an effective medication for the treatment of T2DM, and has been demonstrated to improve glycemic control. The investigators believe that enrolling clinical pharmacist intervention as a part of a multidisciplinary approach and dapagliflozin is necessary to provide better patient care in patients that are on dual or triple oral hypoglycemic agents other than dapagliflozin. Therefore, the hypothesis of this study is that the impact and tolerability of clinical pharmacist-led intervention can be comparable to add on dapagliflozin alone on glycemic control in the management of T2DM.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 138 (actual)
- First submitted
- 30 Nov 2024
- Start date
- 1 Dec 2024
- Primary completion date
- 5 May 2025
- Lead sponsor
- University of Sulaimani
- Diseases
- Type 2 diabetes
- NCT number
- NCT06719661
What you commit to
- Study type: Interventional
- Participants enrolled: 138
- From 1 Dec 2024 to the primary completion date, 5 May 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of type 1 diabetes mellitus.
- History of diabetic ketoacidosis.
- Cognitive impairment or inability to provide informed consent.
Lab values
- Presence of comorbidities (e.g., severe renal impairment (eGFR \< 30 mL/min/1.73m²), thyroid dysfunction, liver dysfunction).
Other
- Pregnancy or breastfeeding.
Who the study is looking for
- Patients with a diagnosis of type 2 diabetes mellitus having either dual or triple therapy, including (metformin, sulfonylurea, and/or DPP-4 inhibitors).
- HbA1c level between 7.0% and 10% and patients with HbA1c above 10% but refusing insulin therapy.
- Willing to provide informed consent.
Age in the registry: 40 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ministry of Higher Education and Scientific research, University of Sulaimani, College of Pharmacy Coordinator of this site? Confirm its status | Sulaymaniyah | Iraq | Unknown status |
| Endocrine and Diabetes Center Coordinator of this site? Confirm its status | Sulaymaniyah | Iraq | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.